PM exposure for Air Pollution

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Air PollutionPM exposure - Other
Eligibility
18 - 35
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether exposure to levels of particulate matter that are close to the current national standard for 24-hour exposure will cause changes in inflammatory and cardiopulmonary function in healthy young people.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Ozone
1
Forceps
1
air filtration with hepa filter

Study Objectives

4 Primary · 8 Secondary · Reporting Duration: Four days

Four days
Ambulatory ECG will be measured 2 hours before each PM exposure day and follow up day in 20 subjects
Ambulatory ECG will be measured 2 hours before each air exposure day and follow up day in 20 subjects
Blood inflammation marker, CRP, will be measured 2 hours before each PM exposure day and follow up day in 20 subjects
Blood inflammation marker, CRP, will be measured 2 hours before each air exposure day and follow up day in 20 subjects
Spirometry will be measured 1 hour before each PM exposure day and follow up day in 20 subjects
Spirometry will be measured 1 hour before each air exposure day and follow up day in 20 subjects
Three days
Ambulatory ECG will be measured 2 hours after each PM exposure day in 20 subjects
Ambulatory ECG will be measured 2 hours after each air exposure day in 20 subjects
Blood inflammation marker, CRP, will be measured 1 hour after each PM exposure day in 20 subjects
Blood inflammation marker, CRP, will be measured 1 hour after each air exposure day in 20 subjects
Spirometry will be measured 1 hour after each PM exposure day in 20 subjects
Spirometry will be measured 1 hour after each air exposure day in 20 subjects

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Ozone
1
Forceps
1
air filtration with hepa filter

Trial Design

2 Treatment Groups

PM exposure
1 of 2
Filtered air exposure
1 of 2

Experimental Treatment

20 Total Participants · 2 Treatment Groups

Primary Treatment: PM exposure · No Placebo Group · N/A

PM exposure
Other
Experimental Group · 1 Intervention: PM exposure · Intervention Types: Other
Filtered air exposure
Other
Experimental Group · 1 Intervention: Filtered air exposure · Intervention Types: Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: four days

Who is running the clinical trial?

U.S. EPA Human Studies FacilityLead Sponsor
1 Previous Clinical Trials
62 Total Patients Enrolled

Eligibility Criteria

Age 18 - 35 · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a ratio of your FEV1/FVC of 80% or higher.
You are between the ages of 18 and 35 years old and are healthy.
You have normal lung function based on NHANES III reference values.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top